Chemotherapy – Erasmus Medical Center – Treatment Details

Survival: 8.2 months
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Temodar
Country: Netherlands
City/State/Province: Rotterdam
Hospital: Erasmus Medical Center
Journal: Link
Date: 4/2002


Patients: This Phase II study involved 27 patients with malignant pleural mesothelioma. None of these patients had been administered prior chemotherapy.

Treatment: The treatment consisted of the chemotherapy drug, temozolomide (temodar).

Toxicity: Grade 3-4 toxicities included hematologic, infection, nausea, vomiting, and arthralgia.

Results: The median overall survival from the time the patient registered in the study was 8.2 months.

Support: Schering-Plough International supported this study. Schering-Plough markets temodar.

Correspondence: J.P. van Meerbeeck

Get your free copy of
“Surviving Mesothelioma” Today!